Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India

Ann Diagn Pathol. 2017 Apr:27:24-27. doi: 10.1016/j.anndiagpath.2016.12.001. Epub 2016 Dec 15.

Abstract

The μ-bcr breakpoint connects exon 19 of BCR with ABL giving rise to the e19a2 transcript corresponding to the p230 fusion protein (micro-BCR breakpoint) which is rarely seen in chronic myeloid leukemia (CML) patients. Here we report three patients with p230 fusion protein presenting with different clinical presentations and diagnosed as CML-CP. These patients received Imatinib (tyrosine kinase inhibitor-TKI) and are still in remission.

Keywords: Chronic myeloid leukemia; Major molecular response (MMR); RQ-PCR; RT-PCR; e19a2 BCR–ABL fusion transcript.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Imatinib Mesylate / therapeutic use*
  • India
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Male
  • Middle Aged
  • Transcription, Genetic
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • BCR-ABL1 fusion protein, human
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl